AstraZeneca, Breast Cancer and ESR1

What To Know About HR+/HER2- Breast Cancer
Medically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases.
AstraZeneca’s Camizestrant Shows Survival Improvement for HR-Positive, HER2-Negative Advanced Breast Cancer with Emergent ESR1 Mutations
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine resistance before disease progression in HR-positive, HER2-negative advanced breast cancer.
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line treatment of individuals with hormone receptor (HR)-positive,
Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer
Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the disease getting worse in a study, a positive outcome in the development of the therapy key to the company's pipeline.
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with the standard-of-care treatment, the company said.
AstraZeneca Breast Cancer Pill Delayed Disease Progression
AstraZeneca Plc’s experimental breast cancer pill helped patients live for longer without their disease worsening, the UK drugmaker said.
Where Does Breast Cancer Most Commonly Spread?
The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...
Too Old to Operate2d
Prognostic Relevance of HER2-Low Status in Breast Cancer
The following is a summary of "HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials ...
Cure Today1d
Delving Into Clinical Research For Patients With Breast Cancer
Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...
Philecia La'Bounty on the Impact Sharing Her Breast Cancer Journey Has Had on Others: 'They Are So Grateful'
Philecia La'Bounty uses social media to encourage others to get screenings, be open about their experiences and share her own battles — and her followers have shown appreciation. Read more about her ...
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...
Stirling mum ready to take on charity walk after breast cancer shock
A Stirling mother diagnosed with breast cancer at 33 is to take part in Breast Cancer Now’s Pink Ribbon Walk. Alex McSharry, ...
Woman Who Received a '36 Month Expiration Date' Cancer Diagnosis 14 Years Ago Now Focuses on Plans for the Future
Stephanie Seban has devoted the last 14 years of her life to being a 'north star' to other young women facing stage four ...
Breast Cancer Market Sees Rapid Growth — Key Insights and Forecasts of Different Breast Cancers for the Coming 10 Years | DelveInsight
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...